

SPEAKER: One of the issues is that people are sent who do not fulfill any of the criteria. So a patient who has basically pretty well-treated for a long time with statin, who has an LDL that is fairly reasonable, but they have really been very stable for a long time, is much less likely to benefit. So if you have a patient who has an LDL between 70 and 100, their last event was several years ago, they have no symptoms, they're doing quite well, that is actually a person who really you did not see very much effect in FOURIER in the subgroup analysis.

The other issue are people without coronary disease, without familial hypercholesterolemia, who may have diabetes or other risk factors or other problems, but they actually are not part of the US package inserts. And therefore, you are not going to be able to get them on PCSK9. So they have to fulfill the package insert, the indication.

So I think that's one issue. The other issue are severe triglyceridemic patients who probably do not have elevated LDLs. And in that case, you have to go along a whole different route decision pathway before you start thinking about a PCSK9.